JPRN-UMIN000052237
Recruiting
未知
Evaluation the clinical utility of KRAS mutation assay using tumor samples (tissue, cytology) and blood samples in patients with pancreatic cancer. - Evaluation the clinical utility of KRAS mutation assay using tumor samples (tissue, cytology) and blood samples in patients with pancreatic cancer.
Conditionspancreatic cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- pancreatic cancer
- Sponsor
- St.Marianna University School of Medicine
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Patients whose participation in this study is decided inappropriate by the principal investigator or subinvestigator. 2\. Patients who are strongly suspected to have a specific type of pancreatic cancer based on tumor markers (e.g., IPMC (intraductal papillary mucinous carcinoma), NEN (neuroendocrine neoplasm)).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A clinical study of relevance to KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerColorectal cancerJPRN-UMIN000013154Department of Medical Oncology, Niigata University Graduate School of Medical and Dental Sciences20
Recruiting
Not Applicable
Clinical relevance of KRAS and GNAS Mutationen in cell-free DNA and circulating epithelial cells regarding the development of pancreatic cancer in IPMN patientsD13.6PancreasDRKS00023356niversitätsklinikum Hamburg-Eppendorf100
Active, not recruiting
Phase 1
A study to investigate changes in the amount of mutations in patients with Resectable Pancreatic Ductal AdenocarcinomaResectable Pancreatic Ductal AdenocarcinomaMedDRA version: 20.0 Level: LLT Classification code 10033602 Term: Pancreatic adenocarcinoma resectable System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-002094-22-ESFundación de investigación de HM Hospitales20
Not yet recruiting
Not Applicable
Prevalence of two mutations (KRAS and BRAF) in patients diagnosed with Colorectal Cancer.CTRI/2013/09/004023Dr Prachi S Patil200
Recruiting
Not Applicable
Comparative analysis of KRAS and EGFR mutation detection in liquid biopsy vs tissue biopsy in patients with NSCLClung cancerNon-small-cell lung carcinoma10038666NL-OMON48625Jeroen Bosch Ziekenhuis150